Clinical Trial Update: Toripalimab in the Neoadjuvant Treatment of BRAF V600 Wild Type Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial update for toripalimab in neoadjuvant treatment of BRAF V600 wild-type melanoma (Stage IIIB-IV) is reported as status UNKNOWN.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Toripalimab (Toripalimab)

Snippet

Sponsor: Fudan University | Conditions: Melanoma Stage IIIB-IV | Phase 2 | Status: UNKNOWN